

Saturday, 21 January 2023

09:25 – 09:30	Welcome and Overview of Working Party	Donal McLornan (United Kingdom) Joanna Drozd-Sokolowska (Poland)
09:30 – 10:20	Session I: A dynamic landscape: An update on classification and prognostication in Myelodysplastic Syndrome in 2023 <i>Chairs: Marie Robin (France) and Donal McLornan (United Kingdom)</i>	
09:30 – 09:45	Update on Myelodysplastic Syndrome classification schemes in 2023 – progress and challenges	Marie Robin (France)
09:45 – 10:00	The IPSS-Molecular: A new molecular era in Myelodysplastic Syndrome prognostication- IPSS-M	Matteo Della Porta (Italy)
10:00 – 10:10	The IPSS-Molecular: Utilising IPSS-M to guide transplantation decisions/ predict outcome. What do we know?	Nico Gagelmann (Germany)
10:10 – 10:20	Q&A	

10:20 – 10:30 Break

10:30 – 11:40	Session II: Improving Transplantation Outcomes for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in 2023 <i>Chairs: Francesco Onida (Italy) and Joanna Drozd-Sokolowska (Poland)</i>	
10:30 – 10:50	Pre-treatment before allo-HCT for in Myelodysplastic Syndrome in the era of novel agents	Case for Yes: Pierre Fenaux (France) Case for No: Katja Sockel (Germany)
10:50 – 11:10	Conditioning for Myelodysplastic Syndrome: a transatlantic debate on optimal strategies	US Practice: Bart Scott (USA) EU Practice: Nicolaus Kroger (Germany)
11:10 – 11:30	Chronic Myelomonocytic Leukaemia: All transplant eligible patients should be offered Allo-HCT	Case for Yes: Joanna Drozd-Sokolowska (Poland) Case for No: Francesco Onida (Italy)
11:30 – 11:40	Q&A	

11:40 – 12:00 Break

12:00 – 12:30 Industry symposium: Slot 1

12:30 – 12:50 Break

12:50 – 13:15	Session III: State of the Art Approaches to Allo-HCT for MDS <i>Chairs: Patrick Hayden (Ireland) and Yves Chalandon (Switzerland)</i>	
	Post Transplant Intervention to improve Outcomes post Allo-HCT for MDS	Ibrahim Yakoub-Agha (France)
13:30 – 14:15	Session IV: VEXAS, a multidisciplinary team united <i>Chairs: Christof Scheid (Germany) and Meral Beksac (Turkey)</i>	
13:30 – 13:45	The point of view of the rheumatologist on role of allo-HCT	Arsene Mekinian (France)
13:45 – 13:55	Allo-HCT in Myelodysplastic Syndrome /VEXAS association	Carmelo Gurnari (Italy)
13:55 – 14:05	Allo-SCT in VEXAS without Myelodysplastic Syndrome	Rafaella Greco (Italy)
14:05 – 14:15	Case presentation: Upfront allo-HCT in VEXAS	Moniek de Witte (Netherlands)
14:15 – 14:30	Q&A	